LDS/Medical Tests/B-Cell Phenotyping Profile for Immunodeficiency and Immune Competence Assessment, Blood

B-Cell Phenotyping Profile for Immunodeficiency and Immune Competence Assessment, Blood

Common variable immunodeficiency (CVID) is a primary immunodeficiency syndrome characterized by defective B-cell differentiation resulting in immunoglobulin deficiency. Clinically CVID may present as recurrent infections, chronic lung disease, autoimmune disorders, gastrointestinal disorders and/or an increased risk of developing lymphoma. Mutations in inducible costimulator expressed on activated T cells (ICOS), CD19 and BAFF-R account for 1-2% cases of CVID and TACI genetic defect accounts for 8-15%. Patients with mutations in the TACI gene are particularly prone to developing autoimmune disease, including cytopenias as well as lymphoproliferative disease. The other mutations each have been reported in only a handful of patients and the pathogenesis is still undefined in more than 50% of CVID patients. A minority of CVID patients (5%-10%) have very low B-cell counts (<1% of peripheral blood leukocytes), while another subset (5%-10%) exhibit noncaseating, sarcoid-like granulomas in different organs and tend to develop a progressive T-cell deficiency. Of all patients with CVID, 25% to 30% have increased numbers of CD8 T cells and a reduced CD4 to CD8 ratio (<1). B-cell phenotyping is also used as an aid in the diagnosis of hyper-IgM syndromes. This disorder characterized by elevated levels of IgM with typically decreased levels of IgG and/or IgA. Patients with hyper-IgM syndromes usually carry a genetic mutation in either CD40L, CD40, activation-induced cytidine deaminase (AID), uracil DNA glycosylase (UNG), or NF-kappa B essential modulator (NEMO) genes. Mutations in CD40L and NEMO are inherited as X-linked recessives, while mutations in CD40, AID and UNG genes are autosomal recessive disorders. Patients with hyper-IgM syndromes carrying one or more of these mutations show defect in isotype class-switching, which leads to a decrease in class-switched memory B cells, with or without an increase in nonswitched memory B cells and IgM-only memory B cells. In addition to its utility in the diagnosis of the above-described primary immunodeficiencies, B-cell phenotyping may be used to monitor B-cell-directed therapies, such as Rituxan (Rituximab) and Zevalin (Ibritumomab tiuxetan).
  • As an aid in diagnosis of common variable immunodeficiency
  • As an aid in diagnosis of hyper-IgM syndromes
  • Therapy monitoring for B-cell directed therapies
  • Therapy monitoring in immunetransplant and HIV infected patients
  • Interpretive report and quantitative information is provided on the various B cell subsets. Table 1 shows B cell panels and subsets.
  • All specimens are evaluated for the total number of CD19+ B cells present in the peripheral blood mononuclear cell population and their results are compared to reference range.
  • B cell phenotyping results should be always correlated with clinical findings.

Table 1. The B cell panels for evaluation of B cell subgroups. Report will represent percentage and absolute counts in cells/microliter.

B cell panel B cell subgroup

CD19+ CD19 expressing B cells (percentage of whole lymphocytes)

CD19+ CD27+ Memory B cells

CD19+ CD27+ IgD+ IgM+ nonswitched or marginal zone memory B cells

CD19+ CD27+ IgD- IgM+ IgM-only expressing memory B cells

CD19+ CD27+ IgD- IgM- class-switched memory B cells

CD19+ IgM+ IgM expressing B cells

CD19+ CD38+ IgM+ transitional B cells

CD19+ CD38+ IgM- plasmablasts

CD19+ CD21- immature B cells

CD19+ CD21+ mature b cells

CD19+ CD20+ Coexpression of CD19 and CD20

B cell numbers may be normal, moderately decreased or in 10% of cases significantly decreased (less than one percent of whole peripheral leukocytes)

Flow cytometry.

Whole Blood EDTA (lavender top).

Stability

Refrigerated: 48 hours

B-cell Activating Factor Receptor (BAFF-R) expression by flow cytometry, B-cell Activating Factor Receptor (BAFF-R) gene mutation analysis TACI gene mutation analysis.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login